Drugs / HB-201
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06373380 | Apr 2024 → Apr 2027 expected | human papillomavirus-related squamous cell carcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04630353 | Jul 2021 → Nov 2023 | oropharynx cancer | AstraZeneca | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05108870 | Aug 2022 → Jan 2027 expected | human papilloma virus infection, oropharynx squamous cell carcinoma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04180215 | Dec 2019 → Jan 2025 | human papillomavirus-related squamous cell carcinoma | Hookipa Biotech GmbH | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06513884 | Dec 2024 → Nov 2029 | oropharynx squamous cell carcinoma | Hookipa Biotech GmbH | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-201 | “HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every (21 days) intravenously for 4 doses (2 doses...” NCT06373380 ↗ |
| Modality | Vaccine | “A anti-cancer vaccine that treats HPV-related cancers.” NCT05108870 ↗ |
| Route | Intravenous | “HB-201 intravenous administration.” NCT04180215 ↗ |